News | May 02, 2024
Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Fluid bed processes: drying, granulating, and coating in just one product container
Subscribe To Our Newsletter & Stay Updated
